Solana

Solana Net Debt

The Net Debt of Solana (HSDT) as of Oct 21, 2026 is -1.08 M USD. In the previous year, Net Debt was -5.13 M USD — a change of -79.00% (higher).

Net Debt

-1.08 MUSD

YoY

-79.00%

Last updated:

Net Debt of Solana is 2024 -1.08 M USD. Net Debt of Solana was 2023 -5.13 M USD. It decreases by -79.00% higher compared to the previous year.

The Solana Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2017
-4.55 M USD
Jan 1, 2018
-11.81 M USD
Jan 1, 2019
-4.82 M USD
Jan 1, 2020
-3.24 M USD
Jan 1, 2021
-11.00 M USD
Jan 1, 2022
-14.44 M USD
Jan 1, 2023
-5.13 M USD
Jan 1, 2024
-1.08 M USD
The Solana Net Debt history
YEARNet DebtYoY
-1.08 MUSD-79.00%
-5.13 MUSD-64.51%
-14.44 MUSD+31.24%
-11.00 MUSD+239.57%
-3.24 MUSD-32.81%
-4.82 MUSD-59.18%
-11.81 MUSD+159.48%
-4.55 MUSD-348.79%
1.83 MUSD-299.31%
-918,177.00USD-217.03%
784,551.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Solana Stock analysis

What does Solana do? Helius Medical Technologies develops and markets the PoNS device, a portable neuromodulation stimulator for neurological wellness. The company focuses on non-invasive platform technologies that enhance the brain's healing ability. The PoNS device is authorized as a class II medical device in Canada for short-term treatment of chronic balance deficits caused by mild-to-moderate traumatic brain injury, used alongside physical therapy. It delivers non-invasive neurostimulation to the tongue to induce neuromodulation. Helius Medical Technologies targets healthcare providers and rehabilitation centers that treat patients with traumatic brain injury. The company's product is designed for use in clinical settings under professional guidance, specifically for patients requiring short-term balance deficit therapy. The PoNS device is positioned as a complementary treatment within physical therapy protocols for neurological rehabilitation. The firm's revenue model is based on the sale of the PoNS device to healthcare institutions and rehabilitation facilities. These institutions purchase the device for use in their treatment programs, leveraging its non-invasive neurostimulation technology to address balance deficits in patients with mild-to-moderate traumatic brain injury. The company's focus on neurological wellness through non-invasive solutions drives its commercial strategy. Solana is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Solana stock

Net Debt of Solana is -1.08 M USD in 2024.

Net Debt of Solana changed from -5.13 M USD to -1.08 M USD, representing a -79.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Solana since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Solana historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Solana

All Key Metrics — Solana